NCT05197920招募中不适用
Diabetes RElated to Acute Pancreatitis and Its Mechanisms (DREAM) An Observational Cohort Study From the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 800
- 试验地点
- 13
- 主要终点
- diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP)
研究概览
简要总结
The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and pathophysiology of diabetes mellitus (DM) following acute pancreatitis (AP).
详细描述
The DREAM investigators will conduct dynamic metabolic testing that includes oral glucose tolerance testing (OGTT), mixed meal tolerance testing (MMTT), and frequently sampled intravenous glucose tolerance testing (FSIGTT). These tests will increase the sensitivity for DM diagnosis (with OGTT) and to assess beta cell function and other pancreatic and enteroendocrine hormones involved in maintaining glucose homeostasis (OGTT, MMTT and FSIGTT). The DREAM research hypotheses are as follows.
- There is a cumulative increase in the risk of any type of DM after an episode of AP, and the development of DM after AP is influenced by several patient and disease-related factors (e.g. age, etiology, disease severity).
- After AP is clinically resolved, there is ongoing subclinical beta cell damage that predisposes to delayed-onset of DM.
- AP triggers an altered immune state in a subset of individuals that predisposes to islet autoimmunity and DM.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of acute pancreatitis (AP) 0-90 days prior to enrollment date
- •Participant fully understands and is able to participate in all aspects of the study, including providing informed consent, completion of case report forms (CRFs), telephone interviews, metabolic testing, and planned longitudinal follow-ups
排除标准
- •Diagnosis of definite chronic pancreatitis (CP) at enrollment based on either of the following criteria met by computed tomography (CT) scan (including non-contrast enhanced) or Magnetic resonance Imaging (MRI) or Magnetic Resonance Cholangiopancreatography (MRCP): (a) Parenchymal or ductal calcifications on CT scan (after excluding the possibility that calcifications are vascular); (b) Intraductal filling defects suggestive of calcifications on MRI and/or MRCP
- •Potential participants with post-endoscopic retrograde cholangiopancreatography (post- ERCP) AP who are hospitalized for <48 hours.
- •Prior (i.e., before enrollment) direct endoscopic necrosectomy of the pancreas or percutaneous necrosectomy or drainage of necrotic collection(s). Participants who require this during follow-up will remain in the study
- •Pancreatic tumors, including ductal adenocarcinoma, neuroendocrine tumors, and metastasis
- •Confirmed or suspected cystic tumor associated with main pancreatic duct dilation, or believed to be the cause of AP (in the site-PI's judgement)
- •Prior pancreatic surgery, including, but not limited to: distal pancreatectomy, pancreaticoduodenectomy, pancreatic necrosectomy, Frey procedure
- •Use of disallowed concomitant medications within 30 days prior to enrollment. A comprehensive list of disallowed medications will be included and routinely updated in the study's Manual of Procedures
- •Severe systemic illness that in the judgement of the investigative team will confound outcome assessments of DM and immunological outcomes or pose additional risk for harms, including: history of solid organ transplant, acquired immunodeficiency syndrome (AIDS), active treatment for cancer (except non-melanoma skin cancer) within 12 months prior to enrollment, chronic kidney disease with estimate glomerular filtration rate (eGFR) < 30 or on dialysis prior to AP, and cirrhosis (based on imaging or biopsy), or any other medical condition that in the opinion of the site-PI carries a life expectancy of <12 months.
- •Known pregnancy at the time of enrollment. Participants who become pregnant during follow-up will remain in the study, but may have modified study assessments for safety
- •Incarceration
- •Any other condition or factor that would compromise the participant's safety or the scientific integrity of the study
结局指标
主要结局
diabetes mellitus (DM) following a qualifying episode of acute pancreatitis (AP)
时间窗: any time during the 36-month longitudinal follow-up period
time to onset of DM during the 36-month longitudinal follow-up period
次要结局
- PROMIS-29 Fatigue(months 3, 12, 24, and 36)
- PROMIS-29 Ability to Participate in Social Roles and Activities(months 3, 12, 24, and 36)
- FSIGTT Total Body Insulin Sensitivity Index (SI)(months 3 and 12)
- Islet Autoantibodies(months 3, 12, 24, and 36)
- MMTT Pancreatic Polypeptide (PP)(months 3, 12, 24, and 36)
- PROMIS Pain Intensity(months 3, 12, 24, and 36)
- PROMIS-29 Physical Function(months 3, 12, 24, and 36)
- OGTT Insulin Sensitivity Index(months 3, 12, 24, and 36)
- FSIGTT Total Body Insulin Sensitivity Index (SI) Disposition Index(months 3 and 12)
- Fecal Elastase(months 3, 12, 24, and 36)
- PROMIS Global Health(months 3, 12, 24, and 36)
- OGTT Insulin Secretion(months 3, 12, 24, and 36)
- MMTT Glucagon(months 3, 12, 24, and 36)
- PROMIS-29 Anxiety(months 3, 12, 24, and 36)
- PROMIS-29 Depression(months 3, 12, 24, and 36)
- PROMIS-29 Sleep Disturbance(months 3, 12, 24, and 36)
- PROMIS-29 Pain Interference(months 3, 12, 24, and 36)
- MMTT Incretin Hormones: GIP and GLP-1(months 3, 12, 24, and 36)
- FSIGTT Acute Insulin Response to Glucose (AIRglu)(months 3 and 12)
- FSIGTT Acute C-peptide Response to Glucose (ACRglu)(months 3 and 12)
研究者
Vernon Michael Chinchilli
Distinguished Professor
Milton S. Hershey Medical Center
研究点 (13)
Loading locations...
相似试验
招募中
不适用
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM MetricsAcute PancreatitisNCT06401577Milton S. Hershey Medical Center800
进行中（未招募）
不适用
Endocrine and Exocrine Secretory Function Alterations After Moderately Severe and Severe Acute PancreatitisAcute Pancreatitis (AP)Diabetes MellitusNCT06590935Shanghai Changzheng Hospital120
招募中
不适用
Prospective Study on Diabetes Mellitus and Its Complications in Newly Diagnosed Adult PatientsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT01055093German Diabetes Center2,000
已完成
不适用
Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian CommunityDiabetes Mellitus, Type 2NCT00339482National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)12,647
已完成
不适用
Examination of the Pancreas in New-onset DiabetesDiabetes MellitusNCT02001337Mayo Clinic79